HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...

Despite the indication of a potential risk, people who receive abnormal results on blood-based colorectal screening tests commonly do not receive the follow-up colonoscopy.

The oncology companion diagnostic market is projected to grow at a CAGR of ~10% over the forecast period. The market is driven by the growing adoption of precision medicine, rising cancer incidence, ...

Raymond James analyst Andrew Cooper maintained a Buy rating on Avantor today and set a price target of $14.00. The company’s shares closed last Friday at $11.36. Take advantage of TipRanks Premium at ...

Raising awareness of medical products and services is a marathon, not a sprint, and Babson Diagnostics has therefore selected a star with plenty of stamina for a long-term partnership. | Raising ...